The P. aeruginosa virulence factor Cif, which inhibits cell-surface expression of the cystic fibrosis transmembrane conductance regulator, has been expressed, purified and crystallized.
Keywords: cystic fibrosis, CFTR, α/β hydrolases, epoxide hydrolases
Abstract
The opportunistic pathogen Pseudomonas aeruginosa secretes a protein that triggers the accelerated degradation of the cystic fibrosis transmembrane conductance regulator (CFTR) in airway epithelial cells. This protein, which is known as the CFTR inhibitory factor (Cif), acts as a virulence factor and may facilitate airway colonization by P. aeruginosa. Based on sequence similarity Cif appears to be an epoxide hydrolase (EH), but it lacks several of the conserved features found in the active sites of canonical members of the EH family. Here, the crystallization of purified recombinant Cif by vapor diffusion is reported. The crystals formed in space group C2, with unit-cell parameters a = 167.4, b = 83.6, c = 88.3 Å, β = 100.6°. The crystals diffracted to 2.39 Å resolution on a rotating-anode source. Based on the calculated Matthews coefficient (2.2 Å3 Da−1), it appears that the asymmetric unit contains four molecules.
1. Introduction
Pseudomonas aeruginosa is a Gram-negative bacterium that is commonly found in soil. However, it is also an opportunistic pathogen that infects humans and forms biofilms that can become highly resistant to antibiotics (Davies & Bilton, 2009 ▶). P. aeruginosa commonly causes lung infections in patients with chronic obstructive pulmonary disease (Dudley et al., 2008 ▶), ventilator-associated pneumonia (Luna et al., 2009 ▶) and community-acquired pneumonia (Koulenti & Rello, 2006 ▶). Additionally, nearly 80% of cystic fibrosis patients develop chronic pulmonary P. aeruginosa infections by the time they reach the age of 18 (Geller, 2009 ▶).
Recently, it has been shown that P. aeruginosa can inhibit the cell-surface expression of cystic fibrosis transmembrane conductance regulator (CFTR) in human airway epithelial cells in culture (Swiatecka-Urban et al., 2006 ▶). This activity was traced to a single secreted protein, dubbed the CFTR inhibitory factor (Cif; MacEachran et al., 2007 ▶). CFTR activity is essential for the maintenance of mucociliary clearance mechanisms in the lung. By subverting CFTR expression, Cif may facilitate airway colonization by P. aeruginosa. In patients with cystic fibrosis, Cif may interfere with therapeutic efforts to restore CFTR function.
Based on sequence analysis, Cif appears to belong to the α/β hydrolase family (Ollis et al., 1992 ▶), a group of proteins with a wide range of enzymatic activities. More specifically, it has been proposed that Cif is a member of the soluble epoxide hydrolase (EH) family (MacEachran et al., 2007 ▶). However, the sequence identity underlying this assignment is low (<30% to confirmed EH members), and a number of residues that form the canonical EH active site exhibit sequence substitutions. Crystallographic data should help to clarify the status of Cif as an epoxide hydrolase and provide a basis for mutagenetic analysis of its CFTR inhibitory action in vivo.
2. Materials and methods
2.1. Protein expression and purification
The plasmid pDPM73 (MacEachran et al., 2007 ▶) expresses full-length Cif, locus PA14_26090 from P. aeruginosa strain PA14 (UniProt accession No. Q02P97), which corresponds to locus PA2934 in strain PA01. The coding sequence is fused directly to a C-terminal hexahistidine tag, and the fusion protein is expressed under the control of a pBAD arabinose-inducible promoter. The accuracy of the construct was verified by DNA sequencing. Residue numbers are reported with respect to the full-length sequence.
Escherichia coli Top10 cells (Invitrogen) were transformed with pDPM73. Single colonies were inoculated and grown overnight in 10 ml lysogeny broth (LB; Bertani, 1951 ▶) containing 100 µg ml−1 ampicillin. Overnight cultures were then diluted 1:100 into LB supplemented with 100 µg ml−1 ampicillin and 0.2%(w/v) l-arabinose and incubated at 310 K with shaking for up to 48 h. Bacterial cells were removed from the medium by centrifugation at 12 000g for 20 min at 277 K followed by filtration through a 0.22 µm pore polyethersulfone membrane (Nalgene) at room temperature.
The filtered supernatant was adjusted to a final concentration of 5 mM imidazole and then passed over a 10 ml column of Ni–NTA Superflow resin (Qiagen) pre-equilibrated with IMAC buffer (500 mM NaCl, 20 mM sodium phosphate pH 7.4) containing 5 mM imidazole. The column was subsequently washed with 200 ml IMAC buffer containing 5 mM imidazole to remove unbound material. Cif was eluted from the column over a five-column-volume gradient running from 5 to 500 mM imidazole in IMAC buffer. Fractions were pooled and concentrated using an Amicon Ultra 15 centrifugation filter with a 10 000 molecular-weight cutoff as per the manufacturer’s directions. The protein was then dialyzed against 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.4, 100 mM NaCl or 20 mM sodium phosphate pH 7.4, 100 mM NaCl. Quantitative amino-acid analysis to determine a reference protein concentration and N-terminal sequence analysis by Edman degradation (Niall, 1973 ▶) were performed at the W. M. Keck Biotechnology Resource Laboratory (Yale University) using purified Cif protein. The A 280 1cm was measured for an aliquot of the same sample and used to calculate an experimental molar extinction coefficient of ∊ = 47 556 M −1 cm−1 (the calculated value was 46 995 M −1 cm−1). For routine measurements, the protein concentration was determined by Bradford assay (Bio-Rad) or by using the A 280 and the Beer–Lambert law A = ∊cl.
2.2. Crystallization of Cif
Purified Cif protein at 5 mg ml−1 in 20 mM HEPES pH 7.4, 100 mM NaCl was submitted to the Hauptman–Woodward Medical Research Institute High-Throughput Screening Facility for microbatch crystallization (Luft et al., 2003 ▶). Vapor-diffusion crystallization was carried out by mixing purified Cif in a 1:1 ratio with reservoir solution in 2 µl sitting drops or 4 µl hanging drops and incubating at 291 K. For sitting-drop experiments, protein was prepared at 5 mg ml−1 in 20 mM HEPES pH 7.4, 100 mM NaCl. For hanging-drop experiments, protein was prepared at 5 mg ml−1 in 20 mM sodium phosphate pH 7.4, 100 mM NaCl. A 100 µl reservoir was used for sitting drops and a 400 µl reservoir was used for hanging drops. The reservoir solution yielding the crystal used for X-ray diffraction consisted of 20%(w/v) polyethylene glycol (PEG) 8000, 100 mM CaCl2, 100 mM sodium acetate pH 5 in a sitting drop.
2.3. Data collection
Prior to data collection, a crystal was transferred into cryoprotectant buffer [20%(w/v) PEG 8000, 100 mM CaCl2, 100 mM sodium acetate pH 5, 20%(w/v) glycerol] and flash-cooled in the nitrogen-gas stream of an Oxford Cryostream 700 operating at 100 K. Diffraction data were collected at 100 K on a MAR345dtb image-plate system (Rayonix) using Cu Kα radiation from a rotating-anode generator (Rigaku) equipped with focusing optics (Genova).
A data set was obtained by collecting 600 oscillation images of 0.3° each over a total of 180°, with an exposure time of 120 s per image.
2.4. Data analysis
Data were processed using the XDS package (Kabsch, 1993 ▶; Table 1 ▶). Self-rotation function analysis was carried out using MOLREP v.9.2 (Vagin & Teplyakov, 1997 ▶) as part of the CCP4 program suite v.6.0.2 (Collaborative Computational Project, Number 4, 1994 ▶). Molecular replacement was carried out using PHENIX v.1.3 (Adams et al., 2002 ▶).
Table 1. Crystallographic and data-collection statistics.
Values in parentheses are for the highest resolution shell.
| Space group | C2 |
| Unit-cell parameters (Å, °) | a = 167.4, b = 83.6, c = 88.3, α = 90, β = 100.6, γ = 90 |
| No. of monomers per ASU | 4 |
| Matthews coefficient (Å3 Da−1) | 2.2 |
| Solvent content (%) | 44.7 |
| Wavelength (Å) | 1.54179 |
| Resolution (Å) | 19.67–2.39 (2.53–2.39) |
| No. of reflections | 173567 (24613) |
| No. of unique reflections | 47107 (7104) |
| Rmerge (%)† | 5.4 (9.5) |
| 〈I/σ(I)〉 | 16.3 (10.1) |
| Completeness (%) | 99.1 (95.9) |
R
merge =
, where I
i(hkl) and I(hkl) are the ith and the mean measurements of the intensity of reflection hkl.
3. Results and discussion
Here, we present conditions for the expression and purification of the Cif protein from P. aeruginosa. The Cif protein contains a predicted secretory signal sequence from residues 1 to 24. Cleavage of the signal sequence following membrane translocation was confirmed by Edman degradation, which yielded the N-terminal sequence 25AEEFPVPN. Highly purified mature hexahistidine-tagged Cif protein was obtained directly from the bacterial growth medium after sterilization by centrifugation and filtration. The bacteria were diluted 1:100 directly from an overnight culture into growth media containing l-arabinose to induce cif-gene expression. Cif protein is visible by Western blotting in the culture supernatant as early as 5 h post-induction, with maximal expression occurring at around 10 h (data not shown). The protein is stable at 310 K and between pH 6 and 9 and is poorly soluble at or below pH 4. Cif can be flash-frozen and stored at 193 K with 10%(w/v) glycerol added as a cryoprotectant.
In order to determine crystallization conditions for Cif, high-throughput screening of 1536 conditions by the microbatch-under-oil method was performed at the Hauptman–Woodward Institute (Luft et al., 2003 ▶). Visual screening identified 12 conditions that yielded promising crystals, all of which included either acetate or citrate as a buffer, were between pH 4 and 5 and contained PEG as the precipitant. These conditions were reproduced by vapor diffusion (Fig. 1 ▶ a). Although in many cases the precipitant, salt and/or protein concentrations identified by microbatch experiments need to be adjusted for use in vapor-diffusion experiments (Chayen, 1998 ▶), in this case we found that the best diffracting protein crystal came from vapor-diffusion experiments using the same conditions that were identified by microbatch screening.
Figure 1.
Crystallization of Cif. (a) A representative crystal of Cif obtained by hanging-drop vapor diffusion. The well solution contained 15%(w/v) PEG 8000, 125 mM CaCl2 and 100 mM sodium acetate pH 5. (b) An SDS–PAGE gel of a washed Cif crystal, visualized by silver staining. A sample of mother liquor from the same drop was washed in an identical manner and gave no visible band (data not shown).
To verify the identity of the crystallized protein, crystals were harvested, washed in well solution and dissolved in SDS–PAGE sample buffer. The protein from a washed crystal runs as a single band on SDS–PAGE at the expected molecular weight (Fig. 1 ▶ b).
Glycerol was tested for its ability to support flash-cooling of the Cif crystallization buffer. 20%(w/v) glycerol was found to be sufficient to permit vitrification, and Cif crystals harvested into the corresponding cryobuffer exhibited excellent diffraction characteristics. A full data set was obtained on a rotating-anode source with a resolution limit of 2.39 Å (R merge = 0.054; see Table 1 ▶).
Cif crystallizes in space group C2. Based on a calculated Matthews coefficient of 2.2 Å3 Da−1, it appears that the asymmetric unit contains four copies of the molecule. Self-rotation function analysis of these data using MOLREP revealed no significant fourfold noncrystallographic symmetry peaks, but did show a strong local twofold peak oriented along the crystallographic a axis (θ = 90°, ϕ = 180°, χ = 180.0°), with a score corresponding to 53% of the crystallographic peak. Additional twofold peaks are found with substantially lower scores (<16%). Since other bacterial α/β hydrolases form dimers (e.g. Agrobacterium radiobacter AD1 epoxide hydrolase; ArEH; Nardini et al., 1999 ▶), it is possible that the crystals reported here contain two dimers in the asymmetric unit. Attempts to determine phase information by molecular replacement using ArEH (PDB entry 1ehy) as a search model failed to yield convincing solutions, presumably reflecting the low sequence identity (22%). Structure determination using experimental phases is under way and the refined structure will be reported separately.
Acknowledgments
Funding support was provided by the Cystic Fibrosis Foundation (MADDEN08G0 to DRM and STANTO97R0 Research Development Program pilot funds to GAO), the NIH (R01-DK075309 to DRM and training grant predoctoral fellowships T32-AI007519 to CDB and T32-DK007301 to DPM) and by a Rosalind Borison Memorial Predoctoral Fellowship to DPM.
References
- Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K. & Terwilliger, T. C. (2002). Acta Cryst. D58, 1948–1954. [DOI] [PubMed]
- Bertani, G. (1951). J. Bacteriol.62, 293–300. [DOI] [PMC free article] [PubMed]
- Chayen, N. E. (1998). Acta Cryst. D54, 8–15. [DOI] [PubMed]
- Collaborative Computational Project, Number 4 (1994). Acta Cryst. D50, 760–763.
- Davies, J. C. & Bilton, D. (2009). Respir. Care, 54, 628–640. [DOI] [PubMed]
- Dudley, M. N., Loutit, J. & Griffith, D. C. (2008). Curr. Opin. Biotechnol.19, 637–643. [DOI] [PubMed]
- Geller, D. E. (2009). Respir. Care, 54, 658–670. [DOI] [PubMed]
- Kabsch, W. (1993). J. Appl. Cryst.26, 795–800.
- Koulenti, D. & Rello, J. (2006). Curr. Opin. Pulm. Med.12, 198–204. [DOI] [PubMed]
- Luft, J. R., Collins, R. J., Fehrman, N. A., Lauricella, A. M., Veatch, C. K. & DeTitta, G. T. (2003). J. Struct. Biol.142, 170–179. [DOI] [PubMed]
- Luna, C. M., Sibila, O., Agusti, C. & Torres, A. (2009). Eur. Respir. J.33, 182–188. [DOI] [PubMed]
- MacEachran, D. P., Ye, S., Bomberger, J. M., Hogan, D. A., Swiatecka-Urban, A., Stanton, B. A. & O’Toole, G. A. (2007). Infect. Immun.75, 3902–3912. [DOI] [PMC free article] [PubMed]
- Nardini, M., Ridder, I. S., Rozeboom, H. J., Kalk, K. H., Rink, R., Janssen, D. B. & Dijkstra, B. W. (1999). J. Biol. Chem.274, 14579–14586. [PubMed]
- Niall, H. D. (1973). Methods Enzymol.27, 942–1010. [DOI] [PubMed]
- Ollis, D. L., Cheah, E., Cygler, M., Dijkstra, B., Frolow, F., Franken, S. M., Harel, M., Remington, S. J., Silman, I., Schrag, J., Sussman, J. L., Verschueren, K. H. G. & Goldman, A. (1992). Protein Eng.5, 197–211. [DOI] [PubMed]
- Swiatecka-Urban, A., Moreau-Marquis, S., Maceachran, D. P., Connolly, J. P., Stanton, C. R., Su, J. R., Barnaby, R., O’Toole, G. A. & Stanton, B. A. (2006). Am. J. Physiol. Cell Physiol.290, C862–C872. [DOI] [PubMed]
- Vagin, A. & Teplyakov, A. (1997). J. Appl. Cryst.30, 1022–1025.

